deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02202759

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Adenocarcinoma of the Stomach Gastroesophageal Junction Expressing Guanylyl Cyclase C
Interventions MLN0264
Updated 8 times since 2017 Last updated: Apr 6, 2017 Started: Aug 4, 2014 Primary completion: Jan 15, 2016 Completion: Jan 15, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business Decision, No Safety or Efficacy Concerns

Other terminated trials from Millennium Pharmaceuticals, Inc.

More terminations from Millennium Pharmaceuticals, Inc.

This PHASE2 trial investigates Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing Guanylyl Cyclase C and is currently terminated or withdrawn. Millennium Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotActive Not Recruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 12 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jul 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Boston, United States , Bruges, Belgium , Brussels, Belgium , Cincinnati, United States , Leuven, Belgium , London, United Kingdom , Madrid, Spain , Manchester, United Kingdom and 7 more locations